KPTI - Karyopharm Therapeutics Inc.

8.77
-0.050   -0.570%

Share volume: 725,180
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$8.82
-0.05
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 25%
Dept financing 16%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.55%
1 Month
38.99%
3 Months
48.90%
6 Months
40.32%
1 Year
27.29%
2 Year
473.20%
Key data
Stock price
$8.77
P/E Ratio 
0.00
DAY RANGE
$8.57 - $9.11
EPS 
-$20.26
52 WEEK RANGE
$3.51 - $10.99
52 WEEK CHANGE
$14.49
MARKET CAP 
125.494 B
YIELD 
N/A
SHARES OUTSTANDING 
18.344 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-26-2025
NEXT EARNINGS DATE
05-07-2025
BETA 
0.63
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$680,501
AVERAGE 30 VOLUME 
$798,919
Company detail
CEO: Richard A. Paulson
Region: US
Website: karyopharm.com
Employees: 380
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Karyopharm Therapeutics Inc. discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries.

Recent news